Drug facts
Tirzepatide while breastfeeding
Quick answer
The label has a lactation section, 8.2. It reports a single-dose clinical study in which tirzepatide was undetectable in 164 of 171 breast milk samples, and states there are no available data on the effects on the breastfed infant or on milk production. It does not tell anyone whether to breastfeed. It tells the prescriber to weigh the benefits of breastfeeding against the clinical need for the drug.
What section 8.2 actually reports1
The section has two parts, a risk summary and the data behind it. The risk summary says the concentration of tirzepatide in breast milk was found to be either undetectable or low compared with the maternal administered dose. The data paragraph gives the study.
The lactation study, as the label describes it
- Participants
- 11 healthy lactating adult females
- Exposure
- A single 5 mg subcutaneous dose
- Result
- Undetectable in 164 of 171 samples assayed
- Limit of detection
- 4 ng/mL in breast milk
- In the other 7 samples
- Cumulative amount over the 28-day sampling window equivalent to less than 0.02% of the maternal administered dose
- Last measurable
- 5 days post-dose
- AUC
- Could not be calculated — insufficient quantifiable concentrations
These measurements describe one dose. They do not measure infant drug concentrations or exposure after months of weekly treatment.
What section 8.2 does not say1
This is the more useful half of the page, because the gaps are specific and the internet fills them confidently.
- It was a single dose. Eleven women, one 5 mg dose, a 28-day sampling window. Nothing on the label describes what happens in milk with once-weekly dosing continued over months.
- No data on the breastfed infant. The label states this in those words. Not reassuring data, not concerning data — none.
- No data on milk production. Same sentence, same status.
- No recommendation either way. Section 8.2 does not advise against breastfeeding and does not endorse it. It sets out a weighing: the developmental and health benefits of breastfeeding, the mother’s clinical need for the drug, and any potential adverse effects on the infant from the drug or from the underlying maternal condition.
A weighing is not an answer, and it is addressed to a clinician. That is who this question ends with.
The Medication Guide says the same thing in fewer words2
The plain-language guide bound to the label puts it this way: tell your healthcare provider if you are breastfeeding or plan to breastfeed; the drug may pass into your breast milk; talk to your healthcare provider about the best way to feed your baby while using it.
The guide and the prescribing information serve different readers. The measured milk concentrations do not answer every question about feeding an individual baby.
Where to read the lactation evidence34
The manufacturer’s single-dose study has posted results in ClinicalTrials.gov under NCT05978713. Its registry record identifies 11 participants given one 5 mg injection. Readers can use that record alongside section 8.2 to check the study design and reported outcomes.
LactMed also summarizes a separate preprint involving five women using 2.5–5 mg weekly. It describes low or unquantifiable milk levels and no infant adverse effects reported by the mothers. That small report does not establish long-term infant safety or effects at higher doses. LactMed advises caution, especially with newborn or preterm infants.
Pregnancy is a different section with a different answer5
Searches for these two topics run together, and the label treats them very differently. Section 8.1 states that weight loss offers no benefit to a pregnant patient and may cause fetal harm, and advises that pregnant patients be told weight loss is not recommended during pregnancy and to discontinue the drug when a pregnancy is recognized. There is also a pregnancy exposure registry run by the manufacturer.
Section 8.3 adds a related point that surprises people: because the drug delays gastric emptying, it may reduce the effectiveness of oral hormonal contraceptives, and the label advises switching to a non-oral method or adding a barrier method for four weeks after starting and for four weeks after each increase in dose.
That contraception statement is a labeling instruction, and it belongs on a page about feeding and fertility even though people rarely go looking for it here. It is not advice from us, and the timing questions it raises belong to a prescriber.
What a compounded vial changes1
On the label — Mounjaro / Zepbound
A lactation study was run, in identified participants, at a known dose, with a stated limit of detection. Every figure on this page traces back to it.
In a compounded vial
Not established.
The label’s study does not establish the properties of a compounded preparation. A compounded vial’s formulation and concentration are among the real differences between a compounded vial and Zepbound. Section 8.2’s numbers describe the approved product and are not transferable.
Where to take this6
To a prescriber, and to whoever is caring for the baby. This is the page on this site where the gap between what the label establishes and what a person actually needs to decide is widest, and no amount of careful reading closes it. If you are weighing the wider risk picture, the label’s reactions reported in 5% or more of participants and the boxed warning and the contraindications that follow from it are the other two places to look. Those adverse-event rates do not measure exposure through breast milk.
Pregnancy and the contraception window are set out separately: what sections 8.1 and 7.2 say →
Sources
- FDA prescribing information for ZEPBOUND (tirzepatide), section 8.2, revision 8/2026 DailyMed
- FDA prescribing information for ZEPBOUND (tirzepatide), Medication Guide, revision 8/2026 DailyMed
- ClinicalTrials.gov, NCT05978713, posted results for the single-dose tirzepatide lactation study Source
- LactMed, Tirzepatide, revision 15 August 2026, including its account of the separate five-participant preprint Source
- FDA prescribing information for ZEPBOUND (tirzepatide), sections 8.1 and 8.3, revision 8/2026 DailyMed
- Compounded Tirzepatide editorial policy and medical disclaimer — this section states our own position and makes no claim from the label Read it